Related Experiment Video
Updated: May 9, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Differential disruption of EWS-FLI1 binding by DNA-binding agents
Changmin Chen1, Diane R Wonsey, Madeleine E Lemieux
1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Fusion of the EWS gene to FLI1 produces a fusion oncoprotein that drives an aberrant gene expression program responsible for the development of Ewing sarcoma. We used a homogenous proximity assay to screen for compounds that disrupt the binding of EWS-FLI1 to its cognate DNA targets. A number of DNA-binding chemotherapeutic agents were found to non-specifically disrupt protein binding to DNA. In contrast, actinomycin D was found to preferentially disrupt EWS-FLI1 binding by comparison to p53 binding to their respective cognate DNA targets in vitro. In cell-based assays, low concentrations of actinomycin D preferentially blocked EWS-FLI1 binding to chromatin, and disrupted EWS-FLI1-mediated gene expression. Higher concentrations of actinomycin D globally repressed transcription. These results demonstrate that actinomycin D preferentially disrupts EWS-FLI1 binding to DNA at selected concentrations. Although the window between this preferential effect and global suppression is too narrow to exploit in a therapeutic manner, these results suggest that base-preferences may be exploited to find DNA-binding compounds that preferentially disrupt subclasses of transcription factors.
Insights
Actinomycin D selectively disrupts EWS-FLI1 binding to DNA in Ewing sarcoma cells. While not therapeutically viable due to narrow concentration windows, this highlights potential for targeted transcription factor disruption.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing sarcoma arises from the EWS-FLI1 fusion oncoprotein, which drives abnormal gene expression.
- Targeting the EWS-FLI1 oncoprotein is crucial for Ewing sarcoma treatment.
Purpose of the Study:
- To screen for compounds that disrupt EWS-FLI1 binding to DNA.
- To investigate the preferential binding disruption of EWS-FLI1 by actinomycin D.
Main Methods:
- Utilized a homogenous proximity assay to screen for DNA-binding disrupting compounds.
- Evaluated compound effects on EWS-FLI1 and p53 DNA binding in vitro.
- Assessed actinomycin D's impact on EWS-FLI1 chromatin binding and gene expression in cell-based assays.
Main Results:
- Actinomycin D preferentially disrupted EWS-FLI1 DNA binding over p53 binding in vitro.
- Low concentrations of actinomycin D selectively blocked EWS-FLI1 chromatin binding and downstream gene expression.
- Higher concentrations of actinomycin D caused global transcriptional repression.
Conclusions:
- Actinomycin D exhibits preferential disruption of EWS-FLI1 DNA binding at specific concentrations.
- The narrow therapeutic window limits actinomycin D's direct application but suggests potential for base-preference-driven targeted therapies.
- Exploiting DNA base preferences could lead to compounds that selectively inhibit specific transcription factor subclasses.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Single-Strand DNA Binding Proteins

